Galena Biopharma Inc. (NASDAQ:GALE) on Apr. 22 announced its results of operations for the quarter ended March 31, 2014. Total revenues for the first quarter of 2014 increased to $5.00 billion from $2.53 billion for the first quarter of 2013. Galena Biopharma Inc. (NASDAQ:GALE) shares after opening at $2.33 moved to $2.42 on last trade day and at the end of the day closed at $2.28. Company price to sales ratio in past twelve months was calculated as 107.52 and price to cash ratio as 5.62. Galena Biopharma Inc. (NASDAQ:GALE) showed a positive weekly performance of 22.58%.
Alexion Pharmaceuticals ‘ (NASDAQ:ALXN) first-quarter 2014 earnings (including stock-based compensation expense) of $1.41 per share easily beat the Zacks Consensus Estimate of $1.09 per share. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares advanced 2.48% in last trading session and ended the day on $156.01. ALXN return on equity ratio is recorded as 11.20% and its return on assets is 8.50%. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) yearly performance is 74.84%.
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, announced that its collaboration partner, Celgene Corporation, presented interim data demonstrating dose dependent increases in hemoglobin in patients with end stage renal disease (ESRD) on hemodialysis. Acceleron Pharma Inc. (NASDAQ:XLRN) shares moved down -4.70% in last trading session and was closed at $31.85, while trading in range of $30.00 – $35.19. Acceleron Pharma Inc. (NASDAQ:XLRN) year to date (YTD) performance is -19.57%.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Net loss for the fourth quarter of 2013 was $8.9 million, or $(0.09) per share, compared to a net loss of $30.2 million, or $(0.37) per share, for the fourth quarter of 2012. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) weekly performance is 5.03%. On last trading day company shares ended up $3.55. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) distance from 50-day simple moving average (SMA50) is -17.89%. Analysts mean target price for the company is $6.69.
Leave a Reply